ES2710506T3 - Nucleósidos sustituidos, nucleótidos y sus análogos - Google Patents
Nucleósidos sustituidos, nucleótidos y sus análogos Download PDFInfo
- Publication number
- ES2710506T3 ES2710506T3 ES13763460T ES13763460T ES2710506T3 ES 2710506 T3 ES2710506 T3 ES 2710506T3 ES 13763460 T ES13763460 T ES 13763460T ES 13763460 T ES13763460 T ES 13763460T ES 2710506 T3 ES2710506 T3 ES 2710506T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- alkyl
- compound
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCCCCCC(OC[C@](CCl)([C@](*)[C@]1F)O[C@]1N(C=CC(N)=N1)C1=O)=O Chemical compound CCCCCCCC(OC[C@](CCl)([C@](*)[C@]1F)O[C@]1N(C=CC(N)=N1)C1=O)=O 0.000 description 32
- OPTASPLRGRRNAP-UHFFFAOYSA-N NC(C=CN1)=NC1=O Chemical compound NC(C=CN1)=NC1=O OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- MHFOMMHDLDVYRO-ZGUVBZSNSA-N Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1F)O[C@@](CO)(CF)[C@H]1O Chemical compound Nc1ncnc2c1nc[n]2[C@@H]([C@@H]1F)O[C@@](CO)(CF)[C@H]1O MHFOMMHDLDVYRO-ZGUVBZSNSA-N 0.000 description 2
- UQXFQEMVZBNBJW-UHFFFAOYSA-N C=[N-]C(C=CN1)=NC1=O Chemical compound C=[N-]C(C=CN1)=NC1=O UQXFQEMVZBNBJW-UHFFFAOYSA-N 0.000 description 1
- SIUWOVNKBWFNJK-YRCORFKGSA-N CC(C(N)=N1)=CN([C@@H]([C@@H]2F)O[C@@](CO)(CCl)[C@H]2O)C1=O Chemical compound CC(C(N)=N1)=CN([C@@H]([C@@H]2F)O[C@@](CO)(CCl)[C@H]2O)C1=O SIUWOVNKBWFNJK-YRCORFKGSA-N 0.000 description 1
- MEXXFZDIIGRNTG-FRHPSRIISA-N CC(C)(C)C(OCOP(OC[C@@]([C@H]([C@H]1F)O)(N=C)O[C@H]1[n]1c(N=C(N)NC2=O)c2nc1)(OCOC(C(C)(C)C)=O)=O)=O Chemical compound CC(C)(C)C(OCOP(OC[C@@]([C@H]([C@H]1F)O)(N=C)O[C@H]1[n]1c(N=C(N)NC2=O)c2nc1)(OCOC(C(C)(C)C)=O)=O)=O MEXXFZDIIGRNTG-FRHPSRIISA-N 0.000 description 1
- UIZCHUIGIMSKOF-KYZVSKTDSA-N CC(C)C(OC[C@](CCl)([C@H]([C@H]1F)OC(C(C)C)=O)O[C@H]1N(C=CC(N1)=O)C1=O)=O Chemical compound CC(C)C(OC[C@](CCl)([C@H]([C@H]1F)OC(C(C)C)=O)O[C@H]1N(C=CC(N1)=O)C1=O)=O UIZCHUIGIMSKOF-KYZVSKTDSA-N 0.000 description 1
- MPHWDETYEPPDHY-BSTOTGJRSA-N CC(C)C(O[C@@H]([C@H]([C@H](N(C=CC(N)=N1)C1=O)O1)F)[C@]1(CO)Cl)=O Chemical compound CC(C)C(O[C@@H]([C@H]([C@H](N(C=CC(N)=N1)C1=O)O1)F)[C@]1(CO)Cl)=O MPHWDETYEPPDHY-BSTOTGJRSA-N 0.000 description 1
- QWSXISQLJRLRLY-KLBPJQLPSA-N CC(C)[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N)=N1)C1=O Chemical compound CC(C)[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N)=N1)C1=O QWSXISQLJRLRLY-KLBPJQLPSA-N 0.000 description 1
- AYIZWIMJZPJUDZ-KLBPJQLPSA-N CC([C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N)=N1)C1=O)=C Chemical compound CC([C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N)=N1)C1=O)=C AYIZWIMJZPJUDZ-KLBPJQLPSA-N 0.000 description 1
- VGPITCDZTMSBRP-RYBJDYITSA-N CC/C=C/[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N)=N1)C1=O Chemical compound CC/C=C/[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N)=N1)C1=O VGPITCDZTMSBRP-RYBJDYITSA-N 0.000 description 1
- DQUNOLHOFZEYBH-KKBFJBPOSA-N CCC(OC[C@](CCl)([C@H]1OC(CC)=O)O[C@@H](C2)[C@]12F)=O Chemical compound CCC(OC[C@](CCl)([C@H]1OC(CC)=O)O[C@@H](C2)[C@]12F)=O DQUNOLHOFZEYBH-KKBFJBPOSA-N 0.000 description 1
- MDGAMVYYQQSPFA-OBXHSSLNSA-N CCCCC(O[C@@H](C1)C11O[C@@H](C)C[C@@H]1OC(CCCC)=O)=O Chemical compound CCCCC(O[C@@H](C1)C11O[C@@H](C)C[C@@H]1OC(CCCC)=O)=O MDGAMVYYQQSPFA-OBXHSSLNSA-N 0.000 description 1
- UYIOOIAYOZXECB-LSBZLQRGSA-N CCCCCCCC(OC[C@](CCl)(C[C@H]1F)O[C@H]1N(C=CC(NC)=N1)C1=O)=O Chemical compound CCCCCCCC(OC[C@](CCl)(C[C@H]1F)O[C@H]1N(C=CC(NC)=N1)C1=O)=O UYIOOIAYOZXECB-LSBZLQRGSA-N 0.000 description 1
- WFPHJCYVIPWYOI-LSCVPOLPSA-N CCCC[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N)=N1)C1=O Chemical compound CCCC[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N)=N1)C1=O WFPHJCYVIPWYOI-LSCVPOLPSA-N 0.000 description 1
- AOXNRGRTYVONPR-UHFFFAOYSA-O CCNC(C=CN1C2[ClH]C(C)(COP(OP(OP(O)(O)=O)=O)=O)C(CO)C2[F]=C)=[NH+]C1=CC Chemical compound CCNC(C=CN1C2[ClH]C(C)(COP(OP(OP(O)(O)=O)=O)=O)C(CO)C2[F]=C)=[NH+]C1=CC AOXNRGRTYVONPR-UHFFFAOYSA-O 0.000 description 1
- LSHSNABVBJLUDE-MEUNMDNISA-N CCOc1nc(N)nc2c1nc[n]2[C@@H]([C@@H]([C@@H]1O)F)O[C@@]1(CO)C=C Chemical compound CCOc1nc(N)nc2c1nc[n]2[C@@H]([C@@H]([C@@H]1O)F)O[C@@]1(CO)C=C LSHSNABVBJLUDE-MEUNMDNISA-N 0.000 description 1
- ZIYXZKDIDKLCIM-UMJHXOGRSA-N CC[C@@](CO)(CC1)OC1N(C=CC(N)=N1)C1=O Chemical compound CC[C@@](CO)(CC1)OC1N(C=CC(N)=N1)C1=O ZIYXZKDIDKLCIM-UMJHXOGRSA-N 0.000 description 1
- BSPXSCRZPVILQE-PKIKSRDPSA-N CC[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N1)=O)C1=O Chemical compound CC[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N1)=O)C1=O BSPXSCRZPVILQE-PKIKSRDPSA-N 0.000 description 1
- NCYCHSNOOHKWEW-WHNOBIIHSA-N CC[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1[n]1c2ncnc(N)c2nc1 Chemical compound CC[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1[n]1c2ncnc(N)c2nc1 NCYCHSNOOHKWEW-WHNOBIIHSA-N 0.000 description 1
- XFTITTRVJAZVIY-OCJNAMCBSA-N CC[C@@](COP(OCOC(C(C)(C)C)O)(OCOC(C(C)(C)C)=O)=O)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N1)=O)C1=O Chemical compound CC[C@@](COP(OCOC(C(C)(C)C)O)(OCOC(C(C)(C)C)=O)=O)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N1)=O)C1=O XFTITTRVJAZVIY-OCJNAMCBSA-N 0.000 description 1
- WFVKZUFCGVFSGV-PKIKSRDPSA-N CNC(C=CN1[C@@H]([C@@H]2F)O[C@@](CO)(CCl)[C@H]2O)=NC1=O Chemical compound CNC(C=CN1[C@@H]([C@@H]2F)O[C@@](CO)(CCl)[C@H]2O)=NC1=O WFVKZUFCGVFSGV-PKIKSRDPSA-N 0.000 description 1
- AFTKPYYHVLLRSZ-YQEUHFCPSA-N CO[C@@](COP(O)(OP(O)(OP(O)(O)=O)=O)=O)([C@H]1O)O[C@@H](C2N(C=CC(N)=N3)C3=O)[C@@]12F Chemical compound CO[C@@](COP(O)(OP(O)(OP(O)(O)=O)=O)=O)([C@H]1O)O[C@@H](C2N(C=CC(N)=N3)C3=O)[C@@]12F AFTKPYYHVLLRSZ-YQEUHFCPSA-N 0.000 description 1
- FYDCSHFQHOCTPU-LOKLDPHHSA-N CSC[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N)=N1)C1=O Chemical compound CSC[C@@](CO)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(N)=N1)C1=O FYDCSHFQHOCTPU-LOKLDPHHSA-N 0.000 description 1
- NOUHPTJCVATYCH-TWOTXZKJSA-N NC(C(F)=CN1[C@@H]([C@@H]2F)O[C@@](CO)(CCl)[C@H]2O)=NC1=O Chemical compound NC(C(F)=CN1[C@@H]([C@@H]2F)O[C@@](CO)(CCl)[C@H]2O)=NC1=O NOUHPTJCVATYCH-TWOTXZKJSA-N 0.000 description 1
- IMKGLUVHCDLKLZ-IBCQBUCCSA-N NC(C=CN1[C@@H]([C@@H]2F)O[C@@](CO)(CBr)[C@H]2O)=NC1=O Chemical compound NC(C=CN1[C@@H]([C@@H]2F)O[C@@](CO)(CBr)[C@H]2O)=NC1=O IMKGLUVHCDLKLZ-IBCQBUCCSA-N 0.000 description 1
- OKNYMNXQBYKYFO-RUQSRZACSA-N NC(NC1=O)=Nc2c1nc[n]2[C@@H]([C@@H]1F)O[C@@](CO)(CCl)[C@H]1O Chemical compound NC(NC1=O)=Nc2c1nc[n]2[C@@H]([C@@H]1F)O[C@@](CO)(CCl)[C@H]1O OKNYMNXQBYKYFO-RUQSRZACSA-N 0.000 description 1
- JINHTBPPPWIQHS-IBCQBUCCSA-N OC[C@](CCl)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(NO)=N1)C1=O Chemical compound OC[C@](CCl)([C@H]([C@H]1F)O)O[C@H]1N(C=CC(NO)=N1)C1=O JINHTBPPPWIQHS-IBCQBUCCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613836P | 2012-03-21 | 2012-03-21 | |
| US13/721,988 US9073960B2 (en) | 2011-12-22 | 2012-12-20 | Substituted nucleosides, nucleotides and analogs thereof |
| PCT/US2013/033018 WO2013142525A1 (en) | 2012-03-21 | 2013-03-19 | Substituted nucleosides, nucleotides and analogs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2710506T3 true ES2710506T3 (es) | 2019-04-25 |
Family
ID=49223309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13763460T Active ES2710506T3 (es) | 2012-03-21 | 2013-03-19 | Nucleósidos sustituidos, nucleótidos y sus análogos |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20190381081A1 (OSRAM) |
| EP (1) | EP2827875B1 (OSRAM) |
| JP (1) | JP6430364B2 (OSRAM) |
| KR (1) | KR102172040B1 (OSRAM) |
| CN (2) | CN104203253A (OSRAM) |
| AP (1) | AP2014007943A0 (OSRAM) |
| AU (2) | AU2013235220C1 (OSRAM) |
| CA (1) | CA2866901C (OSRAM) |
| CL (1) | CL2014002392A1 (OSRAM) |
| CY (1) | CY1122125T1 (OSRAM) |
| DK (1) | DK2827875T3 (OSRAM) |
| EA (1) | EA035159B1 (OSRAM) |
| ES (1) | ES2710506T3 (OSRAM) |
| GE (1) | GEP201706721B (OSRAM) |
| HK (1) | HK1203142A1 (OSRAM) |
| HR (1) | HRP20182030T1 (OSRAM) |
| HU (1) | HUE043054T2 (OSRAM) |
| IL (1) | IL234546B (OSRAM) |
| LT (1) | LT2827875T (OSRAM) |
| ME (1) | ME03502B (OSRAM) |
| MX (2) | MX361460B (OSRAM) |
| NZ (1) | NZ629428A (OSRAM) |
| PH (1) | PH12014502094B1 (OSRAM) |
| PL (1) | PL2827875T3 (OSRAM) |
| PT (1) | PT2827875T (OSRAM) |
| RS (1) | RS58437B1 (OSRAM) |
| SG (2) | SG10201804571TA (OSRAM) |
| SI (1) | SI2827875T1 (OSRAM) |
| SM (1) | SMT201900070T1 (OSRAM) |
| TW (2) | TWI663978B (OSRAM) |
| UA (1) | UA113980C2 (OSRAM) |
| WO (1) | WO2013142525A1 (OSRAM) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA025341B1 (ru) | 2010-09-22 | 2016-12-30 | Алиос Биофарма, Инк. | Замещенные аналоги нуклеотидов |
| CA2812962C (en) | 2010-09-22 | 2020-03-31 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| AU2011349278C1 (en) | 2010-12-22 | 2017-01-19 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| EP2794627B1 (en) | 2011-12-22 | 2018-09-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2013096680A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP2828278A4 (en) | 2012-03-21 | 2015-12-09 | Alios Biopharma Inc | PROCESSES FOR PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS |
| US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
| HUE029038T2 (en) | 2012-05-25 | 2017-01-30 | Janssen Sciences Ireland Uc | Uracil spirooxetan nucleosides |
| CN104955458A (zh) | 2012-11-07 | 2015-09-30 | Z·索 | 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法 |
| US9598457B2 (en) | 2012-12-21 | 2017-03-21 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP2935303B1 (en) | 2012-12-21 | 2021-02-17 | Janssen BioPharma, Inc. | 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv |
| CA2908313A1 (en) | 2013-04-05 | 2014-10-09 | Alios Biopharma, Inc. | Hepatitis c viral infection treatment using a combination of compounds |
| TWI655199B (zh) | 2013-06-26 | 2019-04-01 | 美商艾洛斯生物製藥公司 | 經取代之核苷、核苷酸及其類似物 |
| HK1224229A1 (zh) | 2013-06-26 | 2017-08-18 | Alios Biopharma, Inc. | 取代的核苷，核苷酸及其类似物 |
| AU2014331863C1 (en) | 2013-10-11 | 2019-05-16 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US10119136B2 (en) | 2014-01-09 | 2018-11-06 | Alnylam Pharmaceuticals, Inc. | RNAi agents modified at the 4′-C position |
| EP3102215B1 (en) * | 2014-02-06 | 2021-06-16 | Riboscience LLC | 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication |
| US10059733B2 (en) | 2014-03-03 | 2018-08-28 | Nucorion Pharmaceuticals, Inc. | Gemcitabine analogs |
| EP3160475B1 (en) | 2014-06-24 | 2024-01-03 | Janssen Pharmaceuticals, Inc. | Substituted nucleosides and nucleotides to treat filoviridae infections |
| US9603864B2 (en) | 2014-06-24 | 2017-03-28 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| AU2015294343A1 (en) * | 2014-07-22 | 2017-02-02 | Alios Biopharma, Inc. | Methods for treating paramyxoviruses |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| EP3177299A4 (en) * | 2014-08-05 | 2018-04-04 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
| TWI673283B (zh) * | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | ２’－氯胺基嘧啶酮及嘧啶二酮核苷類 |
| US10358458B2 (en) | 2014-09-26 | 2019-07-23 | Riboscience Llc | 4′-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication |
| US9908914B2 (en) | 2014-10-28 | 2018-03-06 | Alios Biopharma, Inc. | Methods of preparing substituted nucleoside analogs |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| HK1246780A1 (zh) | 2015-03-11 | 2018-09-14 | Janssen Biopharma, Inc. | 氮杂-吡啶酮化合物及其用途 |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| WO2018081449A1 (en) | 2016-10-27 | 2018-05-03 | Alios Biopharma, Inc. | Methods for treating respiratory syncytial virus infection |
| US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
| US11331331B2 (en) | 2017-12-07 | 2022-05-17 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| MX2020007393A (es) | 2018-01-10 | 2020-11-24 | Nucorion Pharmaceuticals Inc | Compuestos de fósforo(n)amidatacetal y fosf(on)atalcetal. |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| MX2021010700A (es) | 2019-03-06 | 2021-10-01 | Glaxosmithkline Ip No 2 Ltd | Compuestos utiles en la terapia del vih. |
| AU2020315394A1 (en) | 2019-07-17 | 2022-02-17 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CA3171648A1 (en) | 2020-02-18 | 2021-08-26 | Gilead Sciences, Inc. | Antiviral compounds |
| CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司（Us） | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
| WO2021216427A1 (en) | 2020-04-21 | 2021-10-28 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds |
| CN111892636A (zh) * | 2020-08-07 | 2020-11-06 | 山东大学 | 一种阿兹夫定的合成方法 |
| PL4323362T3 (pl) | 2021-04-16 | 2025-08-18 | Gilead Sciences, Inc. | Sposoby wytwarzania karbanukleozydów z zastosowaniem amidów |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| AU2023236711A1 (en) * | 2022-03-15 | 2024-10-03 | Rome Therapeutics, Inc. | Compounds and methods for treating disease |
| WO2024103016A1 (en) * | 2022-11-11 | 2024-05-16 | Rome Therapeutics, Inc. | 4'-halomethyl-cytidine phosphoramidates and related compounds and their use in treating medical conditions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| JP4076114B2 (ja) * | 1999-05-12 | 2008-04-16 | ヤマサ醤油株式会社 | ４’−ｃ−エチニルプリンヌクレオシド化合物 |
| DK2251015T3 (da) * | 2000-10-18 | 2013-05-13 | Gilead Pharmasset Llc | Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation |
| SK286630B6 (sk) | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
| US20070032448A1 (en) * | 2002-01-17 | 2007-02-08 | Zhi Hong | Sugar modified nucleosides as viral replication inhibitors |
| RU2004128943A (ru) * | 2002-02-28 | 2005-04-20 | Байота, Инк. (Us) | Средства, имитирующие нуклеотиды, и их пролекарственные формы |
| CN100532388C (zh) * | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| WO2009125841A1 (ja) * | 2008-04-10 | 2009-10-15 | 浜理薬品工業株式会社 | ５－メチルウリジンを出発原料とするエチニルチミジン化合物の製造方法 |
| GB0815968D0 (en) * | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
| WO2010030858A1 (en) * | 2008-09-15 | 2010-03-18 | Enanta Pharmaceuticals, Inc. | 4'-allene-substituted nucleoside derivatives |
| PE20130400A1 (es) * | 2010-07-22 | 2013-04-10 | Gilead Sciences Inc | Metodos y compuestos para tratar infecciones virales por paramyxoviridae |
| EA025341B1 (ru) * | 2010-09-22 | 2016-12-30 | Алиос Биофарма, Инк. | Замещенные аналоги нуклеотидов |
| CA2812962C (en) * | 2010-09-22 | 2020-03-31 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| EP2794627B1 (en) * | 2011-12-22 | 2018-09-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EA201791916A1 (ru) * | 2012-03-13 | 2018-07-31 | Джилид Сайэнс, Инк. | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения |
-
2013
- 2013-03-19 SM SM20190070T patent/SMT201900070T1/it unknown
- 2013-03-19 SG SG10201804571TA patent/SG10201804571TA/en unknown
- 2013-03-19 HK HK15103627.8A patent/HK1203142A1/xx unknown
- 2013-03-19 PL PL13763460T patent/PL2827875T3/pl unknown
- 2013-03-19 LT LTEP13763460.6T patent/LT2827875T/lt unknown
- 2013-03-19 CA CA2866901A patent/CA2866901C/en active Active
- 2013-03-19 NZ NZ629428A patent/NZ629428A/en not_active IP Right Cessation
- 2013-03-19 HU HUE13763460A patent/HUE043054T2/hu unknown
- 2013-03-19 PT PT13763460T patent/PT2827875T/pt unknown
- 2013-03-19 HR HRP20182030TT patent/HRP20182030T1/hr unknown
- 2013-03-19 KR KR1020147029092A patent/KR102172040B1/ko not_active Expired - Fee Related
- 2013-03-19 AP AP2014007943A patent/AP2014007943A0/xx unknown
- 2013-03-19 ES ES13763460T patent/ES2710506T3/es active Active
- 2013-03-19 GE GEAP201313603A patent/GEP201706721B/en unknown
- 2013-03-19 SI SI201331282T patent/SI2827875T1/sl unknown
- 2013-03-19 CN CN201380015428.7A patent/CN104203253A/zh active Pending
- 2013-03-19 CN CN201911178884.9A patent/CN110917205A/zh active Pending
- 2013-03-19 MX MX2014011238A patent/MX361460B/es active IP Right Grant
- 2013-03-19 WO PCT/US2013/033018 patent/WO2013142525A1/en not_active Ceased
- 2013-03-19 EA EA201491493A patent/EA035159B1/ru not_active IP Right Cessation
- 2013-03-19 AU AU2013235220A patent/AU2013235220C1/en not_active Ceased
- 2013-03-19 DK DK13763460.6T patent/DK2827875T3/en active
- 2013-03-19 ME MEP-2019-36A patent/ME03502B/me unknown
- 2013-03-19 RS RS20190171A patent/RS58437B1/sr unknown
- 2013-03-19 SG SG11201405351RA patent/SG11201405351RA/en unknown
- 2013-03-19 JP JP2015501862A patent/JP6430364B2/ja not_active Expired - Fee Related
- 2013-03-19 EP EP13763460.6A patent/EP2827875B1/en active Active
- 2013-03-19 UA UAA201411297A patent/UA113980C2/uk unknown
- 2013-03-21 TW TW107105463A patent/TWI663978B/zh not_active IP Right Cessation
- 2013-03-21 TW TW102110129A patent/TWI639612B/zh not_active IP Right Cessation
-
2014
- 2014-09-09 IL IL234546A patent/IL234546B/en active IP Right Grant
- 2014-09-10 CL CL2014002392A patent/CL2014002392A1/es unknown
- 2014-09-19 MX MX2018015050A patent/MX2018015050A/es unknown
- 2014-09-22 PH PH12014502094A patent/PH12014502094B1/en unknown
-
2018
- 2018-06-07 AU AU2018204024A patent/AU2018204024A1/en not_active Abandoned
-
2019
- 2019-02-06 CY CY20191100160T patent/CY1122125T1/el unknown
- 2019-06-21 US US16/449,164 patent/US20190381081A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2710506T3 (es) | Nucleósidos sustituidos, nucleótidos y sus análogos | |
| ES2702060T3 (es) | Nucleósidos sustituidos, nucleótidos y sus análogos | |
| US10485815B2 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| USRE48171E1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| HK1203076B (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| NZ627179B2 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| HK1203143B (en) | Substituted nucleosides, nucleotides and analogs thereof |